Editorial: Cell-based Therapies for Stroke: Promising Solution or Dead End?

Johannes Boltze¹, Koji Abe², Andrew N Clarkson³, Oliver Detante^{4

5}, Pedro M Pimentel-Coelho^{6

7}, Paulo H Rosado-de-Castro^{8

9

10}, Miroslaw Janowski^{11

12}

Affiliations

¹ School of Life Sciences, University of Warwick, Coventry, United Kingdom.
² Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
³ Department of Anatomy, Brain Health Research Centre and Brain Research New Zealand, University of Otago, Dunedin, New Zealand.
⁴ Stroke Unit, Neurology Department, Grenoble Hospital, Grenoble, France.
⁵ Grenoble Institute of Neurosciences, Inserm U1216, Université Grenoble Alpes, Grenoble, France.
⁶ Instituto de Biofísica Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
⁷ Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa, Rio de Janeiro, Brazil.
⁸ Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
⁹ Department of Radiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
¹⁰ D'Or Institute for Research and Education, Rio de Janeiro, Brazil.
¹¹ Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.
¹² NeuroRepair Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.

Editorial

Johannes Boltze et al. Front Neurol. 2020.

. 2020 Apr 3:11:171.

doi: 10.3389/fneur.2020.00171. eCollection 2020.

Johannes Boltze¹, Koji Abe², Andrew N Clarkson³, Oliver Detante^{4

5}, Pedro M Pimentel-Coelho^{6

7}, Paulo H Rosado-de-Castro^{8

9

10}, Miroslaw Janowski^{11

12}

¹ School of Life Sciences, University of Warwick, Coventry, United Kingdom.
² Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
³ Department of Anatomy, Brain Health Research Centre and Brain Research New Zealand, University of Otago, Dunedin, New Zealand.
⁴ Stroke Unit, Neurology Department, Grenoble Hospital, Grenoble, France.
⁵ Grenoble Institute of Neurosciences, Inserm U1216, Université Grenoble Alpes, Grenoble, France.
⁶ Instituto de Biofísica Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
⁷ Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa, Rio de Janeiro, Brazil.
⁸ Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
⁹ Department of Radiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
¹⁰ D'Or Institute for Research and Education, Rio de Janeiro, Brazil.
¹¹ Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.
¹² NeuroRepair Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.

No abstract available

Keywords: brain; clinical trials; ischemia; mesenchymal stem cells (MSC); stem cells; stroke; translational medicine; treatment.

Comment on

Editorial on the Research Topic Cell-based Therapies for Stroke: Promising Solution or Dead End?

1. Boltze J, Schmidt UR, Reich DM, Kranz A, Reymann KG, Strassburger M, et al. . Determination of the therapeutic time window for human umbilical cord blood mononuclear cell transplantation following experimental stroke in rats. Cell Transplant. (2012) 21:1199–211. 10.3727/096368911X589609 - DOI - PubMed
1. Shen LH, Li Y, Chen J, Zacharek A, Gao Q, Kapke A, et al. . Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab. (2007) 27:6–13. 10.1038/sj.jcbfm.9600311 - DOI - PubMed
1. Yang B, Strong R, Sharma S, Brenneman M, Mallikarjunarao K, Xi X, et al. . Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. J Neurosci Res. (2011) 89:833–9. 10.1002/jnr.22614 - DOI - PMC - PubMed
1. Guzman R, Janowski M, Walczak P. Intra-arterial delivery of cell therapies for stroke. Stroke. (2018) 49:1075–82. 10.1161/STROKEAHA.117.018288 - DOI - PMC - PubMed
1. Cui LL, Golubczyk D, Tolppanen AM, Boltze J, Jolkkonen J. Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy? Ann Neurol. (2019) 86:5–16. 10.1002/ana.25493 - DOI - PubMed